In a paper in Gastroenterology, the researchers note that almost half of patients with IBD, including ulcerative colitis (UC) and Crohn's disease (CD), will develop extraintestinal manifestations during their lifetime, including PSC, which is characterized by inflammation and fibrosis of intrahepatic and extrahepatic bile ducts, eventually evolving to cirrhosis and cancer in most patients.
Although the association between IBD and PSC is "well recognized, uncertainties remain about the magnitude of this problem," Dr. Brigida Barberio of the University of Padova, in Italy, and colleagues point out.
To investigate, they did a systematic review and meta-analysis including 64 global studies with more than 776,000 patients in total.
They report a pooled prevalence of PSC in patients with IBD of 2.16%. The pooled prevalence of PSC in UC or CD separately was 2.47% and 0.96%, respectively. In IBD-unclassified (IBD-U), it was 5.01%.
Overall, the highest prevalence rates of PSC in IBD patients were observed in South America and the lowest in Southeast Asia.
The prevalence of PSC was generally higher in men, patients with more extensive rather than left-sided UC, or ileocolonic or colonic rather than ileal CD.
The data also suggest a higher prevalence of small-duct PSC in CD compared with UC (33.9% versus 19.7%, respectively).
"Our findings provide the first pooled estimates of the burden of PSC in IBD, as well as potential risk factors, which may be important in establishing a prompt diagnosis and initiating appropriate surveillance for relevant gastrointestinal malignancies," Dr. Barberio and colleagues conclude.
"Clinicians who care for patients with IBD must recognize and carefully screen for PSC, as an early appropriate diagnosis is imperative to prevent complications," they suggest.
SOURCE: https://bit.ly/3DfrObt Gastroenterology, online August 19, 2021.
By Reuters Staff
Posted on
Previous Article
« Early switch to DOAC appears safe and effective for intermediate-risk pulmonary embolism Next Article
Severe flares of rheumatic, musculoskeletal disease rare after COVID-19 vaccination »
« Early switch to DOAC appears safe and effective for intermediate-risk pulmonary embolism Next Article
Severe flares of rheumatic, musculoskeletal disease rare after COVID-19 vaccination »
Related Articles
January 29, 2021
Cigarette smoke tied to colorectal neoplasia in IBD patients
December 7, 2023
INSPIRE: Risankizumab meets all efficacy endpoints in UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com